Your browser doesn't support javascript.
loading
Therapeutic inhibition of angiopoietin-like protein 3 for hypertriglyceridaemia and residual risk of ASCVD: beginning of the end or end of the beginning?
Watts, Gerald F; Chan, Dick C.
Affiliation
  • Watts GF; Medical School, Faculty of Health and Medical Sciences, University of Western Australia, GPO Box X2213, Perth, Western Australia 6847, Australia.
  • Chan DC; Lipid Disorders Clinic, Department of Cardiology and Internal Medicine, Royal Perth Hospital, 197 Wellington Street, Perth, Western Australia 6000, Australia.
Eur J Prev Cardiol ; 31(10): 1224-1226, 2024 Aug 09.
Article in En | MEDLINE | ID: mdl-38446991
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hypertriglyceridemia / Angiopoietin-Like Protein 3 Limits: Humans Language: En Journal: Eur J Prev Cardiol Year: 2024 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hypertriglyceridemia / Angiopoietin-Like Protein 3 Limits: Humans Language: En Journal: Eur J Prev Cardiol Year: 2024 Document type: Article Affiliation country: Country of publication: